L5-S1 Disc Fate in Thoracolumbar Arthrodesis Stopping at L5

计划入组 17 人 · 首次发布于 2022 年 10 月 4 日

Hypobaric L5-S1 Study

计划入组 55 人 · 首次发布于 2024 年 7 月 29 日

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

计划入组 7 人 · 首次发布于 2019 年 3 月 4 日

CDKL5 deficiency disorder therapeutic program (Vyant Bio Inc/Cyclica Inc)

AAV gene therapy (CDKL5 deficiency disorder)

CDK-604

THE PARKINSON'S AND MOVEMENT DISORDER INSTITUTE

United States

Rockwell Medical

United States

Vanda Pharmaceuticals

United States

Matica Biotechnology Partners with Childs Cure to Develop Gene Therapy for Rare Genetic Disorders

UCB's Fenfluramine Achieves Positive Phase 3 Results in Ultra-Rare CDKL5 Deficiency Disorder

UCB's Fenfluramine Shows Significant Seizure Reduction in Phase 3 Trial for CDKL5 Deficiency Disorder